PALI - Palisade Bio Inc. Operating income before deduction of amortization

Brandmark of Palisade Bio, Inc. (PALI)

Risks of Phase 2 trial failures and capital shortages are driving volatility, which the GURU.Markets platform reflects through cash-equivalent operating profit, where the parameter value equals 0.00. However, the gastrointestinal recovery business is non-cyclical and independent of macroeconomic trends. A stable staff of researchers and the targeted hiring of pharmacologists currently support the resilience of Palisade Bio, Inc. (PALI).

palisadebio.com - PALI Profit before payment of interest, taxes and amortization (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for Palisade Bio, Inc. (PALI)

- price and consensus price forecast:
Price Rate Chart Palisade Bio Inc.|PALI - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Palisade Bio|PALI - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Price of a Share Palisade Bio|PALI - Company Book Value|Market Capitalization to Net Assets palisadebio.com|PALI - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Palisade Bio, Inc.|PALI - Long-Term Debt to Equity|Short-Term Debt to Equity palisadebio.com|PALI - Company Aggregate Debts|Debts to Net Assets Palisade Bio|PALI - Company Long-Term Debt|Short-Term Debt Volume Palisade Bio|Quick Ratio palisadebio.com
- financial results and valuation multiples details:
PALI - Net Profit|Net Profit Forecast Palisade Bio, Inc.|PALI - P/E Multiple|Projected Price to Earnings Ratio Palisade Bio Inc.|PALI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Palisade Bio|PALI - Operating profit EBITDA|Earnings per share for the last twelve months Palisade Bio|PALI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months palisadebio.com|PALI - Earnings per share growth in current year|Expected net earnings per share growth next year Palisade Bio, Inc.
Summary company analytics:PALI Palisade Bio Inc.
Original product of palisadebio.com

Palisade Bio, Inc. (PALI) faces a critical dependence on a single drug and a constant need for additional equity financing, making operational efficiency a key factor for survival. An analysis of EBITDA allows for an assessment of the real cash flow from core operations, excluding depreciation and debt load, which characterizes this security as a high-risk speculative asset.

Competitors of Palisade Bio, Inc. (PALI)

Operating profit before depreciation charges Phathom|Terns Pharmaceuticals - Operating profit EBITDA|Operating income before deduction of amortization Ironwood Pharmaceuticals IRWD|CURX (curanexpharma.com) - Operating profit before deduction of amortization|IMRN: Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization Evoke Pharma, Inc|Entero - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA RDHL|Operating profit EBITDA jaguar.health (JAGX)|Profit before payment of interest, taxes and amortization Biora Therapeutics, Inc. BIOR|Morphic Therapeutic - Profit before payment of interest, taxes and amortization